Crispr Therapeutics shares tumble after significant earnings miss
Fennec Pharmaceuticals Inc. (NASDAQ:FENC) stock has reached a notable peak, hitting a 52-week high of $7.66. According to InvestingPro data, the company maintains impressive gross profit margins of 90% and boasts a healthy liquidity position with a current ratio of 5.13. This milestone reflects a significant uptrend for the company, which has seen its stock value climb steadily over the past year. Investors have been closely monitoring Fennec Pharma ’s performance, and the recent price level has certainly caught the market’s attention. Analyst targets range up to $15 per share, and InvestingPro analysis reveals 11 additional key insights about FENC’s potential. Over the past year, the company has experienced a 3.63% change, indicating a positive trajectory for the pharmaceutical firm. This 52-week high serves as a testament to Fennec Pharma’s growing presence in the industry and the increasing confidence among its investors. The company maintains a "GOOD" Financial Health score, with analysts expecting positive net income growth this year.
In other recent news, Fennec Pharmaceuticals Inc. reported its fourth-quarter financial results, revealing a revenue of $7.92 million, which slightly exceeded analyst expectations of $7.88 million. However, the company experienced a net loss of $0.06 per share, which was lower than the anticipated loss of $0.19 per share, but wider compared to the previous year’s loss of $0.10 per share. For the full year 2024, Fennec achieved PEDMARK net product sales of $29.6 million, marking a 40% increase year-over-year. The company ended the year with $26.6 million in cash and cash equivalents.
H.C. Wainwright reiterated its Buy rating on Fennec, maintaining a price target of $13. The firm adjusted its revenue forecasts, projecting $46.7 million for 2025 and $87.7 million for 2026, driven by increased adoption of PEDMARK. Fennec also announced the commercial launch of PEDMARQSI in the UK and Germany, enhancing global access to its treatment for preventing hearing loss in pediatric cancer patients. Despite these developments, the company’s stock experienced a decline, attributed to the wider quarterly loss and concerns about profitability. CEO Jeff Hackman expressed optimism about the company’s growth strategy, emphasizing early momentum in 2025 with increased adoption by academic institutions.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.